Extension and Domestic Growth Help the Development of Pharmaceutical Companies
Fu Qiushi, Founding Partner of Phoenix Investment, with a score of 58 points for BCI (Biopharmaceutical Competitiveness & Investment). Although the development of biomedicine industry in China is relatively late, it is estimated that the average growth rate of China's biopharmaceutical market in 2015-2020 will be 18%, higher than the global growth rate of 12%, because China has highly supported the biopharmaceutical industry in terms of talents, capital and policies.
He also mentioned that domestic biopharmaceuticals have the opportunities for antibody and cell therapy. China needs a reasonable and sound capital market grading platform in order to meet the needs of innovative pharmaceutical companies in China for financing. In the next five years, there are two key words in China's biopharmaceutical market: internationalization + innovation / imitation creation, "going global" + "bringing in". We all look forward to a more reasonable and sound direct financing channel in the future and a flexible and pragmatic regulatory and policy system.
KOSBEST have specialized in pharmaceutical machinery for more than 10 years experience, and be dedicated to provide high quality pharmaceutical pulverizer, mixing machine, granulating machine, tablet pressing and relative punch, packaging machinery, and Chinese herbal processing machine, and mainly serve for pharmaceutical and food, daily chemical industry to develop their market with the best customer service and technology support, and solve the questions encountered by our customers from both home and abroad. For more information about various high quality machinery, please be free to email: email@example.com and visit our website: http:/www.kosbest.com/